

LIFE SAVING DRUGS PROGRAM EXPERT PANEL

11th MEETING: 18 February 2022

AGENDA

1. Standing business

- 1.1 Welcome, apologies and potential or actual Conflicts of Interest
- 1.2 Update on actions from previous meetings
- 1.3 Correspondence
- 1.4 Report from the Secretariat

2 Proposed 24 month reviews of existing LSDP medicines

- 2.1 Elosulfase alfa (Vimizim®) - for the treatment of Mucopolysaccharidosis (MPS) Type IVA (Morquio A)
- 2.2 Miglustat (Zavesca®) – for the treatment of Gaucher disease

3 Considerations of LSDP listing

- 3.1 Eliglustat (Cerdelga®) – for the treatment of Gaucher disease

4 Applications for new LSDP medicines

- 4.1 Avalglucosidase alfa (Nexviazyme®) – for the treatment of Pompe disease

5 Other business